Bronwen Loeb

Bronwen M. Loeb, Ph.D. is a patent agent in the firm’s Intellectual Property Practice Group.  She concentrates her practice on US and foreign biotechnology and pharmaceutical patent prosecution.

Intellectual Property.  As an examiner at the United States Patent and Trademark Office, Bronwen examined applications in the gene expression art unit of the recombinant molecular and microbiology section.  Representative technologies include: nucleic acids encoding transcription regulators and methods of using them, nucleic acids encoding promoters and  termination sequences and methods of using them, nucleic acid constructs, and methods of nucleic acid mutation. She has also prepared and prosecuted patent applications in performance fibers technology, including polyester tire cord and industrial polyamide fiber.

Technical Background.  Bronwen worked as a scientist at the Institute of Molecular Biology at the University of Oregon in Eugene, Oregon and at the Massachusetts Institute of Technology in Cambridge, Massachusetts in the lab of Dr. Robert T. Sauer, a renowned protein scientist and member of the National Academy of Sciences.  Her thesis committee included Dr. Peter S. Kim, now president of Merck Research Laboratories and Dr. Uttam Rajbhandary, a world expert in tRNA structure-function work.  Bronwen researched protein-DNA interactions in model prokaryotic and eukaryotic systems and protein structure-function analyses.  Her work includes studies of DNA binding cooperativity, a comprehensive alanine scanning mutagenesis study of Arc repressor including multiply-mutated yet functional versions and in vitro studies of differential tRNA-Ala RNA polymerase III complexes in silkworm using uv crosslinking.  Her research has been published in a variety of scientific peer-reviewed journals.



From the Blog

Privately Held Medical Device and Drug Companies Face Unique Sunshine Act Challenges

As widely reported, the Centers for Medicare and Medicaid Services (“CMS”) recently issued regulations implementing the Sunshine Act provisions of the Affordable Care Act. ...

What Goes Up…Must Come Down: Viagra patent invalidated by Canadian Supreme Court

Pfizer and Teva have been fighting a legal battle over Pfizer’s patent for Viagra in Canada.  The first shot was fired when Novopharm Limited,...

The Perils and Promise of 3D Printing: Are DIY Life Sciences in Your Future?

With news that 3D printing (without question one of the coolest technologies to come down the road in quite some time) can be used...